Is Jasper Therapeutics, Inc. (JSPR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.7% / 30% | 185.5% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 4.7% / 33% | 185.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.3% / 33% | 89.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 4.7% / 33% | 185.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.3% / 33% | 89.7% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -191.1% | |
| Return on Assets (ROA) | -72.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$63M |
| Free Cash Flow | -$63M |
| Total Debt | $2M |
| Debt-to-Equity | 14.7 |
| Current Ratio | 2.6 |
| Total Assets | $80M |
Price & Trading
| Last Close | $1.11 |
| 50-Day MA | $1.35 |
| 200-Day MA | $2.38 |
| Avg Volume | 599K |
| Beta | 3.1 |
|
52-Week Range
$1.04
| |
About Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Jasper Therapeutics, Inc. (JSPR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Jasper Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Jasper Therapeutics, Inc.'s debt ratio?
Jasper Therapeutics, Inc.'s debt ratio is 4.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.3%.
What are Jasper Therapeutics, Inc.'s key financial metrics?
Jasper Therapeutics, Inc. has a market capitalization of $29M. Return on equity stands at -191.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.